Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
April 13 2021 - 4:03PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for respiratory disease, allergy and opioid overdose,
today announced that it will host an investor conference call on
Thursday, April 15, 2021 at 2 p.m. Pacific Time to discuss its
financial and operating results for the fourth quarter and full
year 2020 as well as provide a business update. The company’s press
release concerning its fourth quarter 2020 financial results will
be available after 1 p.m. Pacific Time on April 15, 2021, on its
website at www.adamispharmaceuticals.com, and the company also
expects to file its annual report on Form 10-K for year ended
December 31, 2020 on that date.
Event: Adamis Fourth Quarter and Full Year 2020 Financial
Results Conference CallDate: Thursday, April 15, 2021Time: 2 p.m.
PT (5 p.m. ET)U.S. Dial-in (Toll Free):
1-877-423-9813TOLL/International Dial-in: 1-201-689-8573Conference
ID: 13718220
Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host
the call along with other members of the management team. The call
is open to the public and will provide an update on recent
developments, events that have taken place during the quarter and
certain target milestones and goals for future periods.
Forward-looking statements concerning expectations regarding future
company performance may be made during the conference call.
A live audio webcast of the conference call will also be
available via this link –
http://public.viavid.com/index.php?id=144486, with a replay
available shortly after the live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. Adamis’ naloxone injection
product candidate, ZIMHI, for the treatment of opioid overdose, is
currently under FDA review. Adamis is developing additional
products, including treatments for acute respiratory diseases, such
as COVID-19, influenza, asthma, and COPD. The company’s subsidiary,
US Compounding Inc., compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use by hospitals,
clinics, surgery centers, and vet clinics throughout most of the
United States. For additional information about Adamis
Pharmaceuticals, please visit
www.adamispharmaceuticals.com.
Contact:
Adamis Investor Relations Robert UhlManaging DirectorWestwicke
ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024